Reduction in pulmonary microvascular pressure following cardiopulmonary bypass

Beneficial effects of dobutamine

Albert Yurvati, G. W. Laub, S. P. Sanders, L. J. Dullye, J. B. Reibman, L. B. McGrath

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Pulmonary microvascular pressures (PMVP) have important diagnostic and therapeutic implications when utilized to monitor pulmonary dysfunction after cardiopulmonary bypass. Elevations in PMVP may lead to interstitial pulmonary edema and right ventricular failure. This study evaluated the influence of Dobutamine on PMVP in a trial of 80 consecutive patients undergoing isolated coronary artery bypass grafting (CABG). Forty patients were randomized to the Dobutamine study group and received 5 μg/kg/min of Dobutamine for 24 hours, starting at the completion of bypass. In the control group, patients received postoperative inotropic support as indicated (dopamine [n = 10] or amrinone [n = 6]) by the clinical situation. PMVP values were computed based on continuous hemodynamic monitoring at 6, 12, 18 and 24 hours. Preoperative demographic descriptors and operative variables were comparable between the two groups. Postoperative fluid requirements and nonpulmonary complications were also similar between groups. Upon completion of cardiopulmonary bypass, PMVP (mean ± SD) were PMVP decreased over time in the Dobutamine group, while it did not change in the control group. Clinically mean time to extubation was reduced from 18 to 12 hours (p < 0.06) in the Dobutamine group. We conclude that in patients undergoing cardiopulmonary bypass, the postoperative administration of Dobutamine significantly reduces the PMVP. This may reduce pulmonary interstitial edema and pulmonary complications. Upon completion of cardiopulmonary bypass, PMVP (mean ± SD) were measured at 6 hours, 12 hours, 18 hours and 24 hours. The control group measured 25 ± 5 mmHg, 26 ± 2 mmHg, 27 ± 3 mmHg and 28 ± 3 mmHg. The Dobutamine group measured 25 ± 6 mmHg, 24 ± 3 mmHg, 22 ± 2 mmHg and 18 ± 5 mmHg. PMVP decreased over time in the Dobutamine group (p < 0.001), while it did not change in the control group. Clinically mean time to extubation was reduced from 18 to 12 hours (p < 0.06) in the Dobutamine group. We conclude that in patients undergoing cardiopulmonary bypass, the post-operative administration of Dobutamine significantly reduced PMVP. This may reduce pulmonary interstitial edema and pulmonary complications post cardiopulmonary bypass.

Original languageEnglish
Pages (from-to)231-234
Number of pages4
JournalInternational Surgery
Volume80
Issue number3
StatePublished - 1 Dec 1995

Fingerprint

Dobutamine
Cardiopulmonary Bypass
Pressure
Lung
Pulmonary Edema
Control Groups
Amrinone
Coronary Artery Bypass
Dopamine

Keywords

  • Cardiopulmonary bypass
  • Dobutamine
  • Pulmonary vascular pressure

Cite this

Yurvati, A., Laub, G. W., Sanders, S. P., Dullye, L. J., Reibman, J. B., & McGrath, L. B. (1995). Reduction in pulmonary microvascular pressure following cardiopulmonary bypass: Beneficial effects of dobutamine. International Surgery, 80(3), 231-234.
Yurvati, Albert ; Laub, G. W. ; Sanders, S. P. ; Dullye, L. J. ; Reibman, J. B. ; McGrath, L. B. / Reduction in pulmonary microvascular pressure following cardiopulmonary bypass : Beneficial effects of dobutamine. In: International Surgery. 1995 ; Vol. 80, No. 3. pp. 231-234.
@article{e71e3e9a76cd4818b98dae0d94d58fb9,
title = "Reduction in pulmonary microvascular pressure following cardiopulmonary bypass: Beneficial effects of dobutamine",
abstract = "Pulmonary microvascular pressures (PMVP) have important diagnostic and therapeutic implications when utilized to monitor pulmonary dysfunction after cardiopulmonary bypass. Elevations in PMVP may lead to interstitial pulmonary edema and right ventricular failure. This study evaluated the influence of Dobutamine on PMVP in a trial of 80 consecutive patients undergoing isolated coronary artery bypass grafting (CABG). Forty patients were randomized to the Dobutamine study group and received 5 μg/kg/min of Dobutamine for 24 hours, starting at the completion of bypass. In the control group, patients received postoperative inotropic support as indicated (dopamine [n = 10] or amrinone [n = 6]) by the clinical situation. PMVP values were computed based on continuous hemodynamic monitoring at 6, 12, 18 and 24 hours. Preoperative demographic descriptors and operative variables were comparable between the two groups. Postoperative fluid requirements and nonpulmonary complications were also similar between groups. Upon completion of cardiopulmonary bypass, PMVP (mean ± SD) were PMVP decreased over time in the Dobutamine group, while it did not change in the control group. Clinically mean time to extubation was reduced from 18 to 12 hours (p < 0.06) in the Dobutamine group. We conclude that in patients undergoing cardiopulmonary bypass, the postoperative administration of Dobutamine significantly reduces the PMVP. This may reduce pulmonary interstitial edema and pulmonary complications. Upon completion of cardiopulmonary bypass, PMVP (mean ± SD) were measured at 6 hours, 12 hours, 18 hours and 24 hours. The control group measured 25 ± 5 mmHg, 26 ± 2 mmHg, 27 ± 3 mmHg and 28 ± 3 mmHg. The Dobutamine group measured 25 ± 6 mmHg, 24 ± 3 mmHg, 22 ± 2 mmHg and 18 ± 5 mmHg. PMVP decreased over time in the Dobutamine group (p < 0.001), while it did not change in the control group. Clinically mean time to extubation was reduced from 18 to 12 hours (p < 0.06) in the Dobutamine group. We conclude that in patients undergoing cardiopulmonary bypass, the post-operative administration of Dobutamine significantly reduced PMVP. This may reduce pulmonary interstitial edema and pulmonary complications post cardiopulmonary bypass.",
keywords = "Cardiopulmonary bypass, Dobutamine, Pulmonary vascular pressure",
author = "Albert Yurvati and Laub, {G. W.} and Sanders, {S. P.} and Dullye, {L. J.} and Reibman, {J. B.} and McGrath, {L. B.}",
year = "1995",
month = "12",
day = "1",
language = "English",
volume = "80",
pages = "231--234",
journal = "International Surgery",
issn = "0020-8868",
publisher = "International College of Surgeons",
number = "3",

}

Yurvati, A, Laub, GW, Sanders, SP, Dullye, LJ, Reibman, JB & McGrath, LB 1995, 'Reduction in pulmonary microvascular pressure following cardiopulmonary bypass: Beneficial effects of dobutamine', International Surgery, vol. 80, no. 3, pp. 231-234.

Reduction in pulmonary microvascular pressure following cardiopulmonary bypass : Beneficial effects of dobutamine. / Yurvati, Albert; Laub, G. W.; Sanders, S. P.; Dullye, L. J.; Reibman, J. B.; McGrath, L. B.

In: International Surgery, Vol. 80, No. 3, 01.12.1995, p. 231-234.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Reduction in pulmonary microvascular pressure following cardiopulmonary bypass

T2 - Beneficial effects of dobutamine

AU - Yurvati, Albert

AU - Laub, G. W.

AU - Sanders, S. P.

AU - Dullye, L. J.

AU - Reibman, J. B.

AU - McGrath, L. B.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - Pulmonary microvascular pressures (PMVP) have important diagnostic and therapeutic implications when utilized to monitor pulmonary dysfunction after cardiopulmonary bypass. Elevations in PMVP may lead to interstitial pulmonary edema and right ventricular failure. This study evaluated the influence of Dobutamine on PMVP in a trial of 80 consecutive patients undergoing isolated coronary artery bypass grafting (CABG). Forty patients were randomized to the Dobutamine study group and received 5 μg/kg/min of Dobutamine for 24 hours, starting at the completion of bypass. In the control group, patients received postoperative inotropic support as indicated (dopamine [n = 10] or amrinone [n = 6]) by the clinical situation. PMVP values were computed based on continuous hemodynamic monitoring at 6, 12, 18 and 24 hours. Preoperative demographic descriptors and operative variables were comparable between the two groups. Postoperative fluid requirements and nonpulmonary complications were also similar between groups. Upon completion of cardiopulmonary bypass, PMVP (mean ± SD) were PMVP decreased over time in the Dobutamine group, while it did not change in the control group. Clinically mean time to extubation was reduced from 18 to 12 hours (p < 0.06) in the Dobutamine group. We conclude that in patients undergoing cardiopulmonary bypass, the postoperative administration of Dobutamine significantly reduces the PMVP. This may reduce pulmonary interstitial edema and pulmonary complications. Upon completion of cardiopulmonary bypass, PMVP (mean ± SD) were measured at 6 hours, 12 hours, 18 hours and 24 hours. The control group measured 25 ± 5 mmHg, 26 ± 2 mmHg, 27 ± 3 mmHg and 28 ± 3 mmHg. The Dobutamine group measured 25 ± 6 mmHg, 24 ± 3 mmHg, 22 ± 2 mmHg and 18 ± 5 mmHg. PMVP decreased over time in the Dobutamine group (p < 0.001), while it did not change in the control group. Clinically mean time to extubation was reduced from 18 to 12 hours (p < 0.06) in the Dobutamine group. We conclude that in patients undergoing cardiopulmonary bypass, the post-operative administration of Dobutamine significantly reduced PMVP. This may reduce pulmonary interstitial edema and pulmonary complications post cardiopulmonary bypass.

AB - Pulmonary microvascular pressures (PMVP) have important diagnostic and therapeutic implications when utilized to monitor pulmonary dysfunction after cardiopulmonary bypass. Elevations in PMVP may lead to interstitial pulmonary edema and right ventricular failure. This study evaluated the influence of Dobutamine on PMVP in a trial of 80 consecutive patients undergoing isolated coronary artery bypass grafting (CABG). Forty patients were randomized to the Dobutamine study group and received 5 μg/kg/min of Dobutamine for 24 hours, starting at the completion of bypass. In the control group, patients received postoperative inotropic support as indicated (dopamine [n = 10] or amrinone [n = 6]) by the clinical situation. PMVP values were computed based on continuous hemodynamic monitoring at 6, 12, 18 and 24 hours. Preoperative demographic descriptors and operative variables were comparable between the two groups. Postoperative fluid requirements and nonpulmonary complications were also similar between groups. Upon completion of cardiopulmonary bypass, PMVP (mean ± SD) were PMVP decreased over time in the Dobutamine group, while it did not change in the control group. Clinically mean time to extubation was reduced from 18 to 12 hours (p < 0.06) in the Dobutamine group. We conclude that in patients undergoing cardiopulmonary bypass, the postoperative administration of Dobutamine significantly reduces the PMVP. This may reduce pulmonary interstitial edema and pulmonary complications. Upon completion of cardiopulmonary bypass, PMVP (mean ± SD) were measured at 6 hours, 12 hours, 18 hours and 24 hours. The control group measured 25 ± 5 mmHg, 26 ± 2 mmHg, 27 ± 3 mmHg and 28 ± 3 mmHg. The Dobutamine group measured 25 ± 6 mmHg, 24 ± 3 mmHg, 22 ± 2 mmHg and 18 ± 5 mmHg. PMVP decreased over time in the Dobutamine group (p < 0.001), while it did not change in the control group. Clinically mean time to extubation was reduced from 18 to 12 hours (p < 0.06) in the Dobutamine group. We conclude that in patients undergoing cardiopulmonary bypass, the post-operative administration of Dobutamine significantly reduced PMVP. This may reduce pulmonary interstitial edema and pulmonary complications post cardiopulmonary bypass.

KW - Cardiopulmonary bypass

KW - Dobutamine

KW - Pulmonary vascular pressure

UR - http://www.scopus.com/inward/record.url?scp=0029585823&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 231

EP - 234

JO - International Surgery

JF - International Surgery

SN - 0020-8868

IS - 3

ER -